Division 28
Conference Program

Minneapolis Aug 4-6

Complete program and registration at https://convention.apa.org
August 2022

Hi all! Welcome to the 130th annual American Psychological Association Convention!

It’s great that the Division 28 community will be able to finally meet in person again. I hope that everyone gets the chance to share ideas and talk about the excellent science that Division 28 folks will be presenting. This year’s program features some thought-provoking science spanning a wide range of timely and innovative questions about substance use and psychopharmacology.

I also would like to say that I am extremely grateful for the guidance provided by other members of the Division 28 Executive Committee and for the reviewers who volunteered their time to help create this program. This was definitely a team effort.

If you have Twitter check out our handle (@apadiv28). Our social media team will be posting highlights from the program.

Looking forward to seeing everyone!

Jake Borodovsky
Division 28 Program Chair
Conference map

Most activities will be here
Thursday Aug 4\textsuperscript{th}

\textbf{Outstanding Dissertation & Young Psychopharmacologist Awards} (8:00–8:50am; Room 103C)
- Cassandra L. Boness, PhD, University of New Mexico: \textit{Shifting Conceptualizations from Clinical Description to Mechanisms in Addiction: The ETOH Framework}
- Lorenz S. Neuwirth, PhD, SUNY Old Westbury: \textit{Ameliorating Lead Exposures That Cause Neurodevelopmental Disorders: Preclinical Insights Between The GABA-Shift and Taurine Neuropharmacology}

\textbf{MED Associates Brady/Schuster Award} (9:00–9:50am; Room 207AB)
- John M. Roll, PhD, Washington State University Elson S. Floyd College of Medicine: \textit{Therapeutic Modulation of Reinforcing Value in the Treatment of Substance Use Disorders}

\textbf{Fellows Address: New Fellows Symposium} (10:00–10:50am Room 206AB)
- Mikhail Koffarnus, PhD, University of Kentucky College of Medicine. \textit{Translating Behavioral Economic Principles and Advances in Technology to the Treatment of Substance Use Disorders}
- Robert F. Leeman, PhD, University of Florida. \textit{Etiology of and New Interventions to Ameliorate Alcohol Misuse and Sexual Risk Behavior}

\textbf{Executive Committee Meeting} (1:00–1:50pm \textit{Hilton Minneapolis}, Third Floor, Board Room)
Thursday Aug 4th

**Behavioral Economic Methods to Inform Cannabis Public Policy** (2:00-2:50pm; Room 102A)
- Justin C. Strickland, PhD, Johns Hopkins University School of Medicine: *Behavioral Economic Methods to Inform Medicinal Cannabis Policy*
- Samuel F. Acuff, PhD, University of Memphis: *The Effects of Social Context and Opportunity Cost on the Value of Cannabis*
- Elizabeth R. Aston, PhD, Brown University: *Assessment of Cannabis’ Relative Value: Association Between Demand and Driving Following Cannabis*

**Innovative Approaches to Using Cognitive Behavioral Therapy for Individuals with Opioid Use Disorder** (3:00–4:50pm Room 102E)
- Irene Pericot-Valverde, PhD, Clemson University: *Recovery Coaching and CBT4CBT for People With Opioid Use Disorder: The OVERCOME Study*
- Kelly R. Peck, PhD, University of Vermont: *Prolonged Exposure Therapy for Posttraumatic Stress Disorder in Individuals With Opioid Use Disorder*
- Tanya C. Saraiya, PhD, Medical University of South Carolina: *Developing an Integrated Behavioral Treatment for Women With Opioid Use Disorder and PTSD Symptoms*
- Declan Barry, PhD, Yale University: *Cognitive-Behavioral Therapy for Co-Occurring Chronic Pain and Opioid Use Disorder*
Friday Aug 5th

The Promises and Perils of CBD Psychopharmacotherapy (8:00–9:50am; Room 205A)
- Gustavo Gonzalez-Cuevas, PhD, Idaho State University: The Promises and Perils of CBD Psychopharmacotherapy
- Francisco Guimaraes, PhD, Sch Medicine Ribeirao Preto-Usp: Cannabidiol for the Treatment of Anxiety Disorders
- Jorge Manzanares, PhD, Universidad Miguel Hernandez-CSIC: Role of Cannabidiol in the Regulation of Drug Dependence
- Ilhuicamina Limon, PhD, Benemerita Universidad Autonoma De Puebla: Cannabidiol Participation in Neurodegenerative Disorders

Ketamine and Ketamine-Assisted Psychotherapy – An Overview of the Science and Issues Facing the Field (10:00–10:50am; Room 200A)
- Jennifer Tippett, PsyD, University of Denver: Ketamine and Ketamine-Assisted Psychotherapy – An Overview of the Science and Issues Facing the Field
- Morgan Jolliffe, MA, University of Denver: Identifying Best Mental Health Practices in Ketamine and Ketamine-Assisted Psychotherapy

Division 28 In person and Virtual Poster Session (3:00-3:50pm, Level One, Exhibit Halls BCD)

NIDA/NIAAA ECI Travel Award Poster Session and Social (4:00 – 5:50, Hyatt Regency Minneapolis, Main Level, Nicollet Ballroom AB)

Division 28 Social Hour (7:30pm, Union Rooftop, 731 Hennepin Ave)
NIAAA/NIDA EARLY CAREER INVESTIGATOR POSTER SESSION AND SOCIAL HOUR

NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM & NATIONAL INSTITUTE ON DRUG ABUSE

IN COLLABORATION WITH

SOCIETY OF ADDICTION PSYCHOLOGY – APA DIVISION 50

DIVISION OF PSYCHOPHARMACOLOGY AND SUBSTANCE ABUSE – APA DIVISION 28

AUGUST 5, 2022
4 P.M. - 6 P.M. EST
FRIDAY AUGUST 5TH 2022 7:30PM

JOIN US FOR DIVISION 28 SOCIAL HOUR

Minnesota's only year-round retractable glass enclosed rooftop

UNION ROOFTOP
731 Hennepin Ave Suite 1, Minneapolis, MN 55403

For more details about this event contact Andrea Vásquez Ferreiro at avasquezferreiro@ufl.edu
Become a member!!!

https://www.apadivisions.org/division-28/

Scan the QR code to join!
Saturday Aug 6th

Pharmacology and Toxicology of Minor Cannabinoids---An Industry Collaborative Program of Research (11:00-12:50pm; Room 102A)
• Timothy Lefever, MA, Canopy Growth Corporation: Toxicological Profiles of CBG, CBN, CBC, and THCv in 14-Day Repeated Oral Dosing Rodent Studies
• Elise Weerts, PhD, Johns Hopkins University School of Medicine: Behavioral and Neurocognitive Effects of the Cannabinoid Cannabigerol (CBG)
• Marcel O. Bonn-Miller, PhD, Canopy Growth Corporation: Pharmacokinetics of CBC in a Medical Cannabis Product Also Containing CBD and Delta9-THC
• Erica N. Peters, PhD, Canopy Growth Corporation: Safety, Pharmacokinetics, and Pharmacodynamics of THCv: A Two-Phase, Double-Blind RCT
• Cecelia Bergeria, PhD, Johns Hopkins University School of Medicine: Subjective, Therapeutic, and Adverse Effects of Minor Cannabinoids: CBG, THCv, CBC, and CBN

Division 28 Presidential Address (1:00-1:50pm; Room 203AB)
• Ryan Vandrey, PhD, Johns Hopkins University School of Medicine: Rethinking cannabis product categorization and the need for federal regulation of retail cannabis products

Division 28 Business Meeting (2:00-2:50pm; Room 203AB)
Congrats to the Division 28 Award Winners!

**Outstanding Dissertation Award**

*Cassandra L. Boness*, PhD, University of New Mexico: *Shifting Conceptualizations from Clinical Description to Mechanisms in Addiction: The ETOH Framework*

**Young Psychopharmacologist Award**

*Lorenz S. Neuwirth*, PhD, SUNY Old Westbury: *Ameliorating Lead Exposures That Cause Neurodevelopmental Disorders: Preclinical Insights Between The GABA-Shift and Taurine Neuropharmacology*

**MED Associates Brady/Schuster Award**

*John M. Roll*, PhD, Washington State University Elson S. Floyd College of Medicine: *Therapeutic Modulation of Reinforcing Value in the Treatment of Substance Use Disorders*
Other awesome programs that you won’t want to miss!

Thursday, Aug. 4, 11:00–11:50am

**Symposium 2.0: What's New in Psychopharmacology---FDA-Approvals and Treatments on the Horizon**
Minneapolis Convention Center, Level One, Room 102A
Divisions: 55, 28

Thursday, Aug. 4, 4:00–4:50pm

**Invited Address: Med Associates Distinguished Contributions to Basic Behavioral Research Award**
Minneapolis Convention Center, Level Two, Room 204AB
Divisions: 25, 28

**Participants:** Steven Hursh, PhD, Institute for Behavior Resources, Brookeville, MD. The Story of Economic Behavior Analysis
Other awesome programs that you won’t want to miss!

**Friday, Aug. 5, 9:00–9:50am**

**Symposium 2.0: The Opioid Epidemic: Where We Were, Where We Are, and the Role of Psychology**
Minneapolis Convention Center, Level One, Room 101G
Divisions: 38, 28, 50

**Friday, Aug. 5, 9:00–10:50am**

**Critical Conversations: Exploring Social Factors Contributing to Natural Recovery From Substance Addiction**
Minneapolis Convention Center, Level One, Room 103A
Divisions: 50, 28

**Friday, Aug. 5, 3:00–4:50pm**

**Symposium 2.0: Women Uplifting Women---Strategies for Supporting Women in Psychology**
Minneapolis Convention Center, Level Two, Room 200E
Divisions: 41, 1, 3, 8, 9, 12, 17, 18, 28, 42, 50, 53, APA Committee on Women in Psychology
Other awesome programs that you won’t want to miss!

Saturday, Aug. 6, 8:00–8:50am

Invited Address: 2021 BF Skinner Foundation New Applied Researcher Award
Minneapolis Convention Center, Level One, Room 103D
Divisions: 25, 28

Saturday, Aug. 6, 8:00–9:50am

Symposium 2.0: Computational Psychiatry and Cross-Species Translation
Minneapolis Convention Center, Level One, Room 101H
Divisions: 6, 3, 28, 40

Saturday, Aug. 6, 12:00–12:50pm

Symposium 2.0: Substance Abuse
Minneapolis Convention Center, Level One, Room 103E
Divisions: 6, 28, 50

Saturday, Aug. 6, 3:00–3:50pm

Critical Conversations: The Missing Link to Preventing Opioid Overdose Is Public Approval of Safe Consumption Sites
Minneapolis Convention Center, Level Two, Room 200B
Divisions: 9, 28, 50
Other awesome programs that you won’t want to miss!

From APA Division 28: Psychopharmacology & Substance Abuse

We're looking forward to seeing you at the APA conference in Minneapolis
August 4 - 6, 2022

Scheduled talks of interest to Division 28 members, include:

"Are We All Addicted To Sugar?"
**Nicole Avena**
*When*: Thursday, 2:30 - 3:50
*Where*: Main stage

"Psychodelic Treatment of Tobacco Use Disorder"
**Matt Johnson**
*When*: Thursday, 2:30 - 3:50
*Where*: Main stage

"Using Drugs to Contemplate Liberty"
**Carl Hart**
*When*: Friday, 9 - 10:20
*Where*: Main stage

"Neural Mechanisms of Nicotine Use in Vulnerable Populations: Science as a Platform to Promote Diversity"
**Laura O'Dell Montelongo**
*When*: Thursday, 2:30 - 3:50
*Where*: Main stage

Please contact jacob.borodovsky@dartmouth.edu with questions.
About Division 28

What is Psychopharmacology?

Psychopharmacology is the study of the effects of drugs on behavior, combining methods of psychology and pharmacology. Psychopharmacologists carry out their duties within a number of different settings, including academia, government, private research, industry and clinical. The study of the effects of drugs on behavior has been productively examined in human as well as nonhuman populations, both within and outside the laboratory. The central theme running through the research in this division is the use of behavioral principles as they interact with the effects of pharmacological agents and environmental events.

- **Leadership**
- **Membership**
- **Areas of research**
- **History (check this out this is really interesting!)**